Health Research, Inc.

The State University of New York

University of Rochester

The Research Foundation of Suny

Allan R Oseroff

Ravindra Kumar Pandey

William R Potter

Amy L Gryshuk

Lalit Goswami

Thomas Foster

Michael Detty

Chad Eric Bigelow

Munawwar Sajjad

Yihui Chen

Chao Liu

Haridas Pudavar

Indrajit Roy

Sandra O Gollnick

Sherry Davies

Masako Abe

Tymish Y Ohulchansky

David Hilmey

Stephanie Pincus, Legal Representative

Hani A Nabi

Suresh Pandey

Janet Morgan

Mahabeer Dobhal

William J Cottrell

Paras N Prasad

An instrument for photodynamic therapy applies treatment light from a dye laser, white light, and ultraviolet fluorescence excitation light from an LED onto a lesion and surrounding areas in a time-multiplexed manner. The reflected white light is analyzed in a spectrometer to determine a correction for the dynamic optical spectral properties of the patient's tissue. Light emitted by fluorescence from the lesion and the surrounding areas is analyzed in another spectrometer, and the results are corrected in a computer, using the correction. An optical switch has been developed for the instrument, using a bistable solenoid and a sled.

Photodynamic therapy with spatially resolved dual spectroscopic monitoring

Tetrapyrrolic photosensitizers and imaging agent compounds having A, B, C, and D rings and having a reduced B ring and an oxidized D ring. The compounds preferably have a purity of at least 95 percent and preferably have a fused system connected at an unsaturated carbon atom of the C ring nearest the D ring and at the unsaturated carbon atom between the C and D rings. The invention also includes a method of making the compounds at over 95 percent yield by starting with a B and D ring oxidized tetrapyrollic compound and dissolving it in a halogenated hydrocarbon solvent and treating it with sufficient nitroalkane solution of FeCl6HO to oxidize the D ring and separating the resulting organic layer and drying.

B ring reduced-D ring oxidized tetrapyrrolic photosensitizers for photodynamic therapy and tumor imaging

This invention describes a first report on the synthesis of certainI-labelled photosensitizers related to chlorines and bacteriochlorins with long wavelength absorption in the range of 660-800 nm. In preliminary studies, these compounds show a great potential for tumor detection by positron emission tomography (PET) and treatment by photodynamic therapy (PDT). The development of tumor imaging or improved photodynamic therapy agent(s) itself represent an important step, but a dual function agent (PET imaging and PDT) provides the potential for diagnostic body scan followed by targeted therapy.

Porphyrin-based compounds for tumor imaging and photodynamic therapy

A compound having preferential localization in tumor tissue relative to normal tissue, a preferential electromagnetic absorption at a wavelength between about 660 and 900 nm, and a fluorescence at a wavelength shifted from the preferential absorption by at least +30 nm and preferably at least +50 nm. The compound further preferably destroys tumor tissue in which it is absorbed when exposed to light at its preferential absorption wavelength. In a preferred embodiment of the invention, the compound is a conjugate of a tumor avid tetrapyrrole compound with a fluorescent dye, and more preferably the fluorescent dye is an indocyanine dye such as indocyanine green. The tumor avid tetrapyrrole compound is preferably a porphyrin derivative selected from the group consisting of chlorins, bacteriochlorins, purpurins and derivatives thereof.

Adduct of fluorescent dye and tumor avid tetrapyrrole

A tetrapyrollic photosensitizer compound having at least one pendant &#x2014;CHCHCON(CHCON(CHCOOH))or &#x2014;N(CHCOOH)group or esters thereof said tetrapyrollic compound being a chlorin, bacteriochlorin, porphyrin, pyropheophorbide, purpurinimide, or bacteriopurpurinimide. Desirably the compound has the formula: or a pharmaceutically acceptable derivative thereof, wherein R-Rand Rare various substituents and Ris substituted or unsubstituted &#x2014;CHCHCON(CHCON(CHCOOH)); or &#x2014;N(CHCOOH). The invention also includes a method of treatment by photodynamic therapy by treatment with light after injecting the compound and a method of imaging by fluorescence after injection of the compound.

Water soluble tetrapyrollic photosensitizers for photodynamic therapy

A tetrapyrollic photosensitizer compound having at least one pendant &#x2014;CHCHCON(CHCON(CHCOOH))or &#x2014;N(CHCOOH)group or esters thereof said tetrapyrollic compound being a chlorin, bacteriochlorin, porphyrin, pyropheophorbide, purpurinimide, or bacteriopurpurinimide. Desirably the compound has the formula: or a phamaceutically acceptable derivative thereof, wherein R-Rand Rare various substituents and Ris substituted or unsubstituted &#x2014;CHCHCON(CHCON(CHCOOH)); or &#x2014;N(CHCOOH). The invention also includes a method of treatment by photodynamic therapy by treatment with light after injecting the compound and a method of imaging by fluorescence after injection of the compound.

The present invention is directed to novel photosensitive compounds that can be replicated with great certainty and provide applications for photodynamic therapy.

Core modified porphyrins

Growing community of inventors

Buffalo, NY, United States of America

Allan R Oseroff